<?xml version="1.0" encoding="UTF-8"?>
<p>For 
 <italic>in vivo</italic> drug testing, C57BL/6J mice were purchased from Charles River Laboratories. Tivozanib-treated mice (0.5 mg kg
 <sup>−1</sup>, per os) were infected as described above, whereas pimozide (20 mg kg
 <sup>−1</sup>, via os)- and TOFA (25 mg kg
 <sup>−1</sup>, via intraperitoneal)-treated mice were subcutaneously infected with CHIKV C21 in the footpad (10
 <sup>3</sup> PFU). Mouse health status and body weight were scored daily.
</p>
